A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma-Reference-Cited by-同舟云学术

A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma

Published:2024-05 Issue: Volume:202 Page:114009
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Sacco Joseph J.,Jackson Richard,Corrie Pippa,Danson Sarah,Evans T.R. Jeffry,Ochsenreither Sebastian,Kumar Satish,Goodman Andrew,Larkin James,Karydis Ioannis,Steven Neil,Lorigan Paul,Plummer Ruth,Patel Poulam,Psarelli Eftychia,Olsson-Brown Anna,Shaw Heather,Leyvraz Serge,Handley Louise,Rawcliffe Charlotte,Nathan Paul

Funder

AstraZeneca UK Limited

Cancer Research UK

Publisher

Elsevier BV

Reference18 articles.

1. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase ii trial by the spanish multidisciplinary melanoma group (GEM-1402);Piulats;J Clin Oncol,2021

2. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase ii study;Pelster;J Clin Oncol,2021

3. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172);Nathan;Eur J Cancer,2019

4. Overall survival benefit with tebentafusp in metastatic uveal melanoma;Nathan;N Engl J Med,2021

5. FOCUS phase 3 trial results: percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A);Zager;J Clin Oncol,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis;Human Vaccines & Immunotherapeutics;2024-07-14